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Vitamin D binding protein (DBP) is the major carrier protein of 25-hydroxyvitamin D (25(OH) D) in the circulation, where it
may serve roles in maintaining stable levels during times of decreased 25(OH) availability and in regulating delivery of 25(OH) D
to target tissues. Several genetic polymorphisms of DBP have been described that lead to phenotypic changes in the protein that
may affect affinity, activity, and concentration. These polymorphisms have been linked with alterations in bone density in several
populations.OneofthemechanismsbywhichDBPmayalterbonehealthinvolvesregulatingvitaminDbioavailability.DBP-bound
vitaministhoughttoberelativelyunavailabletotargettissues,andthusalterationsinDBPlevelsoraffinitycouldleadtochangesin
vitamin D bioactivity. As a result, functional vitamin D status may differ greatly between individuals with similar total 25(OH) D
levels. Additionally, DBP may have independent roles on macrophage and osteoclast activation. This review will summarize recent
findings about DBP with respect to measures of bone density and health.
1. Introduction
Vitamin D binding protein (DBP) is a 58kDa circulating
alphaglobulinproducedprimarilybytheliver.Whileinitially
knownasGc-globulin(group-specificcomponentofserum),
it has been renamed for its ability to bind the vast majority
(>85%) of circulating 25-hydroxyvitamin D (25(OH) D).
D B Pi sam e m b e ro ft h es a m ep r o t e i nf a m i l ya sa l b u m i na n d
is produced at relatively stable levels throughout life, though
high estrogen states like pregnancy can promote increased
production [1]. While it is best known for its vitamin D
binding properties, it may have roles in other biological
processes as well. Additional actions attributed to DBP
include binding of extracellular actin and transport of fatty
acids. DBP also appears to protect the complement factor
C5a from proteolytic degradation, effectively enhancing its
action as a chemotactic protein [2]. A deglycosylated form of
DBP, DBP-macrophage activating factor (DBP-MAF), is able
to promote activation of macrophages and osteoclasts, and
even native DBP may have effects on osteoclasts [3]. Given
both its vitamin D binding characteristics and its potential
direct actions on bone resorption, considerable interest has
been generated in the scientific community surrounding the
potential actions of DBP on bone metabolism and health.
Fueling this interest has been the discovery of significant
interindividual differences in DBP levels. Early data points
to associations between differences in DBP levels and bone
density [4]. While some differences in DBP can be explained
b a s e do nc l i n i c a lc h a r a c t e r i s t i c s ,am o d e r a t ea m o u n to f
variation in both levels and action appears to be driven by
genetic polymorphisms.
2. Polymorphisms of DBP
Although over 120 variant forms of DBP have been recorded
[5], three main phenotypic alleles have been described in the
literature, initially identified based on their electrophoretic
migration pattern. The slowest migrating is GC2, followed by
GC1S (slow) and GC1F (fast) [6]. These phenotypic variants
differ in both the associated concentration of DBP in the
serum and their affinity for 25(OH) D and possibly other
characteristics (see Table 1)[ 7]. In addition, there is substan-
tialracialandgeographicvariationwiththesedifferentforms.
GC1F,whichisassociatedwiththelowest DBPconcentration
when present in homozygotes (though controversy remains
aboutthistopic),ismorecommonindark-skinnedindividu-
als, particularly those of African descent, while GC2 is more
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Table 1: Common phenotypic variants of DBP and associated characteristics.
Phenotype rs7041 (D432E) rs4588 (T436K) DBP levels in homozygotes 25(OH) D affinity
GC1F t (D: asp) c (T: thr) Lowest Highest
GC1S g (E: glu) c (T: thr) Highest Intermediate
GC2 t (D: asp) a (K: lys) Intermediate Lowest
The three most widely studied variants of DBP include GC1F, GC1S, and GC2, which are distinguished by their SNPs rs7041 and rs4588. The associated
nucleotide and amino acid changes are presented, along with known data on DBP levels in homozygotes and affinity for 25(OH) D (derived from Powe et al.
[9] and Arnaud and Constans [7]). Conflicting data regarding these relationships remain [10].
commoninCaucasians[1].Thestructuraldifferencesinthese
polymorphic forms are quite limited. Gc1S and GC2 differ
from Gc1F only by single amino acid differences, tracked to
single nucleotide polymorphisms. The rs7041 polymorphism
leads to a substitution of g for t and, thus, a glutamate for
a na s p a r t a t ei nG 1 S .Th er s 4 5 8 8p o l y m o r p h i s ms u b s t i t u t e s
a for c and, thus, lysine for threonine in GC2 [8]. As each
individualhastwocopiesoftheDBPgene,thecombinationof
these various alleles may influence the levels and behavior of
DBP on target tissues, including bone. Most studies of DBP’s
effects on bone in humans have focused on characterizing
these allelic variants and attempting to correlate them with
bone health.
3. DBP Polymorphisms and Bone Health
As women are at highest risk for the development of
osteoporosis later in life, studies of DBP and bone disease
have been concentrated in women. One of the first studies,
originating over 20 years ago, looked at DBP in 258 nonblack
elderly women, aged 65–90 [11]. The subjects were randomly
selected as part of a prospective study of falls and fractures
and underwent bone densitometry measurements at three
sites (calcaneus, proximal radius, and distal radius) as well
as height measurement. Phenotyping of DBP was performed
based on electrophoretic analysis. Over two-thirds of the
individuals in this study had either Gc1S/1S or Gc1S/2
diplotype, with less than three percent carrying the lowest-
DBP allelic combination, Gc1F/1F. This lack of heterogeneity
m a yh a v el i m i t e dt h ea b i l i t yo ft h ea u t h o r st od e t e c tc l i n i c a l
differences between these alleles and, indeed, no statistically
significant association with these allelic forms was found for
bone mineral density (BMD), with respect to height or with
respecttootherbonymeasurements(os-calcisareaandelbow
breadth), even after multivariable adjustment for age and
obesity.
Several more recent studies, however, are at odds with
these early findings. While most studies have focused on
the two major SNPs (rs7041 and rs4588) seen in Caucasians
and people of African descent, Ezura et al. examined 13DBP
polymorphisms in a cohort of 384 postmenopausal Japanese
women [12]. Five of these variants were significantly asso-
ciated with BMD; one of these SNPs (−39𝐶 > 𝑇)w a s
found in the promoter region, while the remainder were
intronic. The combination of the exonic D432E (rs7041,
which defines GC1S) with another SNP (IVS1 + 827𝐶 >
𝑇) was most strongly associated with BMD, suggesting that
examining multiple SNPs simultaneously may be optimal
for determining the effects of these polymorphisms on bone
health, at least in some populations. Neither D432E nor
T436K (rs4588) was significantly associated with DBP when
examined in isolation in this population.
Studies in Western populations have yielded slightly
different results. Lauridsen and colleagues used isoelectric
focusing to determine Gc phenotype in 595 postmenopausal
white Danish women as part of the Danish Osteoporosis
Prevention Study, a 20-year partly randomized multicenter
study of osteoporotic fracture prevention with hormone
replacement therapy [13]. They identified large populations
of GC1/GC1 and GC1/GC2 and a smaller population of
GC2/GC2. They examined associations of these phenotypes
with a historical evaluation of fracture number (prior to
enrollment in the cohort), baseline bone mineral content
(BMC), and baseline BMD at various sites (including fore-
arm,lumbarspine,andhip).SubjectswithGC1/GC1werethe
most likely to have had a fracture, while GC2/GC2 subjects
had the least, with GC1/2 individuals falling into an inter-
m e d i a t eg r o u p .Th ee ff e c t sw e r ep a r t i c u l a r l yp r o n o u n c e df o r
low-energy fractures. Despite these historical clinical associ-
ations, there neither were differences in measured BMC or
BMD between the subgroups nor were there any differences
in circulating markers of bone turnover. The authors also
examined the effects of plasma DBP concentration; while no
effectwasseenintheoverallpopulation,DBPconcentrations
were negatively correlated with BMD at all sites in women
who had a history of fractures. These results suggest that
there may be subpopulations in which DBP phenotype is
particularly important. Notably, a separate analysis of this
cohort demonstrated unusually high DBP levels in subjects
withGC1F/GC1F,conflictingwithmorerecentdata[10].This
discrepancy may reflect changes in DBP assays over time or
other biological differences in the relatively small number of
i n d i v i d u a l sw i t ht h i sp h e n o t y p e( 𝑛=1 7 ).
While the mechanism underlying the observed associa-
tions was not clear, a subsequent analysis found that levels of
both 25(OH) D and 1,25-dihydroxyvitamin D (1,25(OH)2 D)
werelowerinGC2/GC2individualscomparedwithGC1/GC1
(with GC1/GC2 again falling between the two) [14]. Another
study of 741 European white women similarly examined
the relationship between the two common DBP SNPs and
25(OH)Dconcentrations[15].Thisstudysimilarlyfoundthat
the SNP variant associated with GC2 (rs4588) was associated
w i t hl o w e rp l a s m a2 5 ( O H )Da n da l s of o u n ds i m i l a rr e s u l t s
for the polymorphism at rs7041 associated with GC1F. How-
ever, DBP polymorphisms explained only 2% or less of theInternational Journal of Endocrinology 3
variationin25(OH)Dlevels,similartotheamountexplained
by vitaminD intake.Athirdstudy extended thesefindingsto
infants and toddlers. Carpenter et al. studied the relationship
between DBP polymorphisms and 25(OH) D levels in over
750urbanUSchildren,6–36monthsofage[8].Childrenwere
g e n o t y p e db a s e do nt h et w om o s tc o m m o n l ys t u d i e dS N P s
(rs7041 and rs4588). Only the rs4588 SNP appeared to be
associatedwith25(OH)Dlevels.Whenassessedbydiplotype,
genetic variation in DBP did appear to be associated overall
with variation in 25(OH) D level, though the effect was again
mild. As with prior studies, the polymorphism associated
with the GC2 phenotype was linked with lower 25(OH) D
levels. The authors also concluded based on multivariate
analysis that only some of the genotypic associations of DBP
with 25(OH) D could be attributed to differences in plasma
DBP concentrations. Additional factors may be differences
in affinity for 25(OH) D between the phenotypes or in other
aspects of DBP action.
A recent study examined associations of DBP genotype
with 25(OH) D levels, parathyroid hormone (PTH) levels,
and bone density in a group of 231 Finnish children aged 7–
19 [16]. Genotyping was done based only on rs4588, which
identifiestheGC2phenotypeasdistinctfromtheGC1forms,
though only 6% of the study population was homozygous
for GC2. GC2 homozygosity was again associated with the
lowest 25(OH) D levels. DBP levels were not examined.
The authors found that the effect of DBP genotype differed
by gender. GC1 variants were associated with higher bone
density only in boys, though another measure of bone health
(strengthandstrainindex)wassignificantinbothgenders.As
expected,25(OH)Dlevelsweregenerallyinverselyassociated
with PTH levels, including within genotypes. Despite this,
though GC2 homozygotes had the lowest 25(OH) D levels,
they also had the lowest PTH levels. The authors hypothesize
that this may reflect differential amounts of bound versus
unbound 25(OH) D as a fraction of total 25(OH) D, thus
affecting the PTH-vitamin D relationship. How this affects
bone health itself is still unclear. Of note, rs4588 is located in
exon11,whichisthoughttoaffectthenon-vitaminDbinding
activities of DBP, including potential effects on macrophage
and osteoclast activation as part of DBP-MAF activity, so the
effects on vitamin D biology may not be the only relevant
factor to changes in bone density.
The gender differences in the association of DBP with
B M Dh a v ea l s ob e e ns e e ni na d u l tp o p u l a t i o n s .X ue t
al. studied 1873 individuals from 405 Caucasian European
families, using the newer metric of compression strength
index (CSI), which accounts for weight and the periosteal
diameter of the femoral neck in the interpretation of femoral
BMD [17]. Unlike most studies of DBP polymorphisms, the
authors included 12SNPs in the analysis, none of which
were the common rs7041 and rs4588. Two were found to
be significantly associated with CSI (rs222029 and rs222020;
both are intronic), but gender-specific analysis revealed that
these associations were driven entirely by men. The authors
h y p o t h e s i z et h a tt h i sm a yb ed u et oag r e a t e ra s s o c i a t i o n
b e t w e e n2 5 ( O H )Da n dm u s c l es t r e n g t hi nm a l e s ,b u tt h e
exact reason for the observed gender differences in this and
other studies remains elusive.
Other studies have echoed the observations that DBP is
associatedwithbonedensityinmen.RapadofoundthatDBP
concentration was positively associated with lumbar spine
BMDin140elderlymen(aged55–90)[18].Non-SNPvariants
of DBP may also be important in men. One polymorphism
is a variable number of (TAAA)𝑛-Alu sequences in intron 8,
which has been associated with an effect on plasma levels of
DBP[4].Al-Oanziandcolleaguesstudiedthispolymorphism
in 170 male subjects that included 114 healthy males and 56
with idiopathic osteoporosis and low trauma fractures [19].
Specific alleles of the (TAAA)𝑛-Alu repeat expansion were
associated with bone mineral density as well as DBP concen-
trations. However, studies of DBP and bone health in men
havenotuniversallybeenpositive.Astudyof211menover70
years of age found no association of either the conventional
D B Pp h e n o t y p e so r(TAAA)𝑛 repeat expansion genotypes in
BMD or markers of bone turnover [20]. Replication of these
genetic associations is key for validating early findings.
4. DBP and Vitamin D Bioavailability
The majority of both 25(OH) D and 1,25(OH)2 Dc i r c u l a t e
in large part bound to DBP (85–90%). A lesser fraction is
bound weakly to albumin, while less than 1% circulates in
its free form [21]. Animal studies suggest that DBP serves
to protect 25(OH) D from degradation, prolonging its half-
life and protecting against vitamin D deficiency [22]. In
addition to stabilizing vitamin D concentrations, however,
DBP appears to slow the action of vitamin D in the intestine
and reduce uptake by the liver. Additionally, other studies
havedemonstratedthatDBPdiminishestheactionofvitamin
D on target tissues such as monocytes and keratinocytes
[23, 24]. These findings have supported the application of the
freehormonehypothesistovitaminD.Thismodelpostulates
thatonlyhormonesthatarenotboundtothecarrierproteins
a r ef r e et oe n t e rc e l l sa n di n d u c eb i o l o g i c a la c t i o n s[ 25].
Followingtheidentificationofbindingcoefficientsof25(OH)
Da n d1 , 2 5 ( O H ) 2 Dw i t ha l b u m i na n dD B P[ 21, 26], relative
fractions of these hormones in bound and unbound states
c o u l db ec a l c u l a t e df r o mt h e i rt o t a lc o n c e n t r a t i o n sa n dt h e
concentrationsofalbumin and DBP. Vitamin D behaves sim-
ilartootherhormonessuchastestosterone,wherebindingto
a specific binding protein is much stronger than to albumin.
Albumin-bound hormone can be considered similar to free
h o r m o n ea si ti sa v a i l a b l et oa c to nt a r g e tt i s s u e s ,w h i l e
binding-protein bound hormone cannot. Indeed, given this
weak binding, fluctuations in albumin level (e.g., in many
disease states) would not be expected to markedly affect
vitamin D bioactivity. Our group adapted the previously
validated formulae for bioavailable testosterone to vitamin D
to define bioavailable vitamin D concentrations [27, 28]. In a
study of 49 healthy young adults, we found that bioavailable
25(OH) D (not bound to DBP) was highly correlated with
bone density, while total 25(OH) D was not [28].
A follow-up study in a cohort of incident hemodialysis
patients similarly found that bioavailable 25(OH) D was
positively correlated with serum calcium and negatively
correlated with PTH levels, while 25(OH) D displayed no4 International Journal of Endocrinology
such relationship [29]. In a recent publication, we examined
the effects of race and DBP allelic variants in a large cohort
of black and white Americans, focusing on the commonly
studied SNPs rs7041 and rs4588 [9]. Blacks displayed lower
2 5 ( O H )Da n dD B Pl e v e l s ,b u th i g h e rB M D .G e n e t i cp o l y -
morphismexplainedthevastmajorityofthevariationinDBP
levels (79.4%). Though higher PTH levels were associated
withlower25(OH)Dlevelsasexpected,blackshadmarkedly
lower 25(OH) D levels compared with whites within each
quintile of PTH. This discrepancy appeared to be explained
by assessment of bioavailable 25(OH) D, which was similar
betweenthetworacesanddisplayedsimilarassociationswith
PTH when examined by quintile. Some notable race-specific
effects, however, were found. The T variant of rs7041 was
associated with lower DBP in both races but lower 25(OH)
D levels only in blacks, while the A variant at rs4588 was
associated with higher DBP in both races but lower 25D only
in whites. BMD was associated with total and bioavailable
25(OH)Dlevelsonlyinwhites.TheDBPdiplotypeassociated
with the lowest DBP levels (Gc1F/1F) was common in blacks,
but rare in whites. These marked racial differences are likely
to be key for interpreting and assessing generalizability of
studies involving both vitamin D and DBP.
Ongoing controversies remain with the interpretation
of DBP levels. Assays are not standardized and can yield
different results from one another, either due to differential
binding to different DBP isoforms or due to assay nonspeci-
ficity [30–32]. While most studies of free or bioavailable
vitamin D have relied on calculated values based on binding
coefficients,moreprecisemethodsforassessingDBPbinding
are being developed. One recent study included a novel
immunoassay that aims to directly measure free 25(OH) D
andcomparedthiswiththeconventionalcalculatedapproach
in 155 individuals, including some cirrhotic and some preg-
nant subjects [33]. This study found that, as expected, DBP
a n da l b u m i nl e v e l sw e r et h el o w e s ti ns u b j e c t sw i t hc i r r h o s i s
b u tt h a tm e a s u r e df r e e2 5 ( O H )Dw a st h eh i g h e s t .D e s p i t e
the higher DBP levels in pregnancy, however, measured
free 25(OH) D was not different in pregnant women than
in nonpregnant subjects. While calculated and measured
free 25(OH) D levels were correlated, this correlation was
relatively weak, explaining only 13% of the variability, and
was particularly weak in African Americans. The authors
also found that only measured and total 25(OH) D levels
correlated with PTH. Additional assays to directly assess
free and bioavailable vitamin D are under development, and
all will require additional validation and comparison with
clinical outcomes to determine the optimal assay.
5. Summary and Future Directions
A renewed interest in DBP has accompanied a general
upswing in vitamin D research in recent years and, indeed,
DBP may be key for understanding and interpreting vita-
min D’s action, particularly with respect to bone health.
NumerousstudieshavefoundthatDBPlevelsandphenotypic
variants correlate with both total 25(OH) D levels and
B M Da n do t h e rm e a s u r e so fb o n eh e a l t h .H o w e v e r ,t h e s e
associationshavenotbeenconsistentintheliterature,andthe
magnitude of these effects is still of unclear clinical signifi-
cance. Furthermore, many studies of DBP variants have been
performedinspecific,homogenouspopulationsandhowwell
thesefindingstranslatemorebroadlyisnotwellknownatthis
time.Additionallargepopulationstudiesareneededtobetter
definetheroleofDBPanditsvariantsonbiologicaloutcomes.
TheconceptofbioavailablevitaminD,thefractionofvitamin
D not bound to DBP, may explain some of DBPs effects on
bone health and will be explored further as dedicated assays
aredeveloped.Additionalactions,includingDBP’sactionson
monocyteandosteoclastactivation,mayalsobeimportantin
determining bone density. As yet unrealized is the potential
for drugs that influence DBP or its binding that might be
useful in novel approaches to the treatment or prevention
of bone disease. This remains in exciting avenue for future
investigation.
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